Now Janus has it's own facilities but what sets them apart I think is the selling of doors and security entry systems and other parts to other players in the industry and other companies. Take a little tour through this website and you will se what I mean.. if all over the nation there is to be more storage then there's more of the special doors that Janus has (CEO invented) // The security entry system seems especially well placed now.-- INTRODUCING, THE ALL-IN-ONE, ON-DOOR SMART LOCK Nokē ONE is an electronic smart lock that fits on the outside of the individual self-storage unit door. These smart locks fit seamlessly to both roll-up and swing doors and were designed to improve the security of individual self-storage units while also making life easier for site managers by automating the lock check and overlocking processes. SMART ENTRY SYSTEM Our Nokē Smart Entry system is truly changing the self-storage access control game. Our Smart Entry is a Bluetooth electronic lock and total access control system that allows your customers to easily access your self-storage facility and their unit from their smart device. What does that mean exactly? You can say goodbye to the frustration and inefficient time suck of customers losing their keys or not being able to remember their gate codes. With advanced technology included inside every unit controller and electronic locks and motion sensors INSIDE every door, this security solution is here to change the way you think about protecting your investment while also making your customers’ lives easier. Another game-changing element of the Nokē Smart Entry system is digital key sharing, where tenants can go into the app on their phone and grant temporary unit access to a friend, family member, or anyone who needs to grab an item from the storage unit. The digital key can be revoked at any time, and an activity log keeps track of exactly when the unit was accessed during the key sharing time frame. https://www.janusintl.com/access-co...2077e851|b65b0238-daad-4571-b3bf-fc1cc8a02da3
ADDING JANUS INT. TO OUR LIST-! -----$9,000 WILL BECOME $18,000 ----- Janus International Group, Inc. (JBI) NYSE - NYSE Delayed Price. 9.21-0.13(-1.39%)
TIMING WISE-- IT BEING SUMMER... OUTLOOK Therapeutics- - Outlook Therapeutics, Inc. Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) Pre-launch commercial activities continue in preparation for potential approval and launch of ONS-5010 ISELIN, N.J., May 15, 2023 (GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2023. “We continue to make significant progress in our pre-launch activities as we approach our PDUFA goal date set for August 29, 2023, just three short months away. These initiatives are focused on positioning Outlook Therapeutics as an upcoming leader in the anti-VEGF space by meeting FDA requirements for an ophthalmic approval. The ONS-5010 Biologics License Application (BLA) was submitted and accepted for filing by the FDA as a 351(a) stand-alone BLA. We believe ONS-5010, if approved, has the potential to be the standard of care in the retinal anti-VEGF space and look forward to potentially bringing to market the first FDA-approved ophthalmic formulation of bevacizumab,” commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics.
In Oct of 22' there was a bunch of insider buying at Outlook including a 111,000 share purchase @$1.28. So these cats have sat and waited a long time and we can slip in now and get jiggy? YUP.-
A screaming summer buy... but when-? Outlook Therapeutics, Inc. (OTLK) @$1.15 NasdaqCM - NasdaqCM Real Time Price. 1.1500+0.0200(+1.77%) $1,000 Turns into $5,000-$7,000 Guggenheim starts Outlook Therapeutics at Buy on Lytenava opportunity 04/03 OTLK As previously reported, Guggenheim analyst Eddie Hickman initiated coverage of Outlook Therapeutics with a Buy rating and $5 price target. The anti-VEGF market is currently dominated by several blockbuster branded products and an emerging biosimilar line-up, but up to 40% of anti-VEGF injections are done with off-label bevacizumab purchased from compounding pharmacies, which is something not officially approved by the FDA, the firm tells investors. Outlook Therapeutics has developed an on-label ophthalmic formulation of bevacizumab to potentially replace the reformulated version and Guggenheim believes "the Street is overlooking the significant market opportunity that could emerge" if Lytenava is approved and compounding pharmacies are forced to cease production of the off-label formulation. The firm notes that the Lytenava PDUFA date is coming up on August 29.
I'm super into Drones. You have your RCAT your DPRO but underwater drones... so important with that pesky China... These Kraken guys are certainly in the lead they have alredy sold to NATO navies (Polish and Danish) and certain other countries including US of course.
Roth MKM sees winners and losers from internet gaming deals » 09:42 DKNG, RSI, PENN, NGMS, INSE, BRAG